Scinai Immunotherapeutics Ltd. (SCNI)

NASDAQ: SCNI · Real-Time Price · USD

0.2730

-0.0030 (-1.09%)

Jul 31, 2026, 4:00 PM EDT - Market closed

Scinai Immunotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2.96	1.66	1.96	4.87	14.08	17.37
Cash & Short-Term Investments	2.96	1.66	1.96	4.87	14.08	17.37
Cash Growth	199.60%	-15.43%	-59.67%	-65.40%	-18.99%	492.54%
Accounts Receivable	0.15	0.07	0.08	-	-	-
Total Trade Receivables	0.15	0.07	0.08	-	-	-
Other Current Assets	0.5	0.32	0.34	0.58	0.3	0.47
Total Current Assets	3.61	2.05	2.39	5.45	14.37	17.84
Net Property, Plant & Equipment	13.97	9.57	11.06	12.03	12.7	14.19
Total Assets	17.59	11.63	13.45	17.47	27.07	32.04

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	0.78	0.41	0.38	0.54	0.72	1
Accrued Expenses	1.55	0.85	1.01	0.85	1.24	1.07
Current Portion of Leases	0.35	0.33	0.42	0.4	0.38	0.38
Total Current Liabilities	2.69	1.59	1.81	1.78	2.34	2.44
Long-Term Debt	0.29	0.29	0.26	19.37	20.08	27.16
Long-Term Leases	2.86	1.64	1.4	0.8	1.08	1.45
Other Long-Term Liabilities	-	-	0	0.1	5.33	-
Total Long-Term Liabilities	3.14	1.94	1.67	20.26	26.49	28.61
Total Liabilities	5.83	3.52	3.47	22.04	28.83	31.05

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Preferred Stock	5.63	5.63	5.63	-	-	-
Additional Paid-in Capital	130.14	130.06	123.63	119.51	116.08	113.08
Accumulated Other Comprehensive Income	-1.74	-1.74	-1.74	-1.74	-2.01	-2.06
Retained Earnings	-122.27	-125.85	-117.54	-122.34	-115.84	-110.04
Shareholders' Equity	11.76	8.1	9.98	-4.57	-1.76	0.98
Total Liabilities & Equity	17.59	11.63	13.45	17.47	27.07	32.04

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	3.5	2.27	2.09	20.56	21.54	28.99
Net Cash (Debt)	-0.53	-0.61	-0.12	-15.69	-7.47	-11.61
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.19	-0.26	-0.15	-40.17	-39.61	-82.26
Book Value	11.76	8.1	9.98	-4.57	-1.76	0.98
Book Value Per Share	4.20	3.47	12.37	-11.70	-9.34	6.96
Tangible Book Value	11.76	8.1	9.98	-4.57	-1.76	0.98
Tangible Book Value Per Share	4.20	3.47	12.37	-11.70	-9.34	6.96

SEC Filings: 10-K · 10-Q